门诊对照莫西.pdf

International Journal of Antimicrobial Agents 29 (2007) 56–61 Efficacy and safety of 3-day azithromycin versus 5-day moxifloxacin for the treatment of acute bacterial exacerbations of chronic bronchitis Marcus Zervos a,∗, Fernando J. Martinezb , Guy W. Amsden c , Constance D. Rothermel d , Glenda Treadway d a Henry Ford Hospital, Detroit, MI, USA b University of Michigan Medical Center, Ann Arbor, MI, USA c The Bassett Healthcare Research Institute’s Clinical Research Division and Department of Pharmaceutical Care Services, Bassett Healthcare, Cooperstown, NY, USA d Pfizer Inc., New York, NY, USA Received 10 July 2006; accepted 9 August 2006 Abstract Antibiotic therapy is of clinical benefit in certain patients with acute exacerbations of chronic bronchitis (AECB). In this randomised, investigator-blinded, multicentre trial, azithromycin (500 mg once a day (qd) for 3 days) was compared with moxifloxacin (400 mg qd for 5 days) for the treatment of outpatients with AECB (forced expiratory volume in 1 s (FEV1) 35%). Of 342 patients randomised to either treatment, 169 received azithromycin and 173 received moxifloxacin. The mean age in the azithromycin and moxifloxacin groups was 56.4 years and 55.5 years, respectively. In the intent-to-treat analysis, clinical success rates for azithromycin and moxifloxacin were comparable at Days 10–12 (90% versus 90%, respectively) and Days 22–26 (81% versus 82%, respectively). Among patients who were culture-positive at baseline for Strept